Discounted Cash Flow
United Therapeutics Corp.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $1.6b | $713.7m | $605.6m | 44.6% | $16.29 |
| 2017 | $1.7b (7.9%) | $417.9m (-41.4%) | $387.9m (-35.9%) | 24.2% (-45.7%) | $9.50 (-41.7%) |
| 2018 | $1.6b (-5.7%) | $589.2m (41.0%) | $594.0m (53.1%) | 36.2% (49.4%) | $13.54 (42.5%) |
| 2019 | $1.4b (-11.0%) | $-104.5m (-117.7%) | $-290.3m (-148.9%) | -7.2% (-119.9%) | $-2.39 (-117.7%) |
| 2020 | $1.5b (2.4%) | $514.8m (592.6%) | $696.4m (339.9%) | 34.7% (581.2%) | $11.65 (587.4%) |
| 2021 | $1.7b (13.6%) | $475.8m (-7.6%) | $477.4m (-31.4%) | 28.2% (-18.7%) | $10.60 (-9.0%) |
| 2022 | $1.9b (14.9%) | $727.3m (52.9%) | $663.7m (39.0%) | 37.6% (33.1%) | $15.98 (50.8%) |
| 2023 | $2.3b (20.2%) | $984.8m (35.4%) | $747.6m (12.6%) | 42.3% (12.6%) | $21.04 (31.7%) |
| 2024 | $2.9b (23.6%) | $1.2b (21.4%) | $1.1b (44.5%) | 41.5% (-1.8%) | $26.44 (25.7%) |
| 2025 | $3.2b (10.6%) | $1.3b (11.7%) | $1.0b (-3.7%) | 41.9% (1.0%) | $30.13 (14.0%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.